Pilkington makes breakthrough

A WEIGHTY piece of research from stockbroker Societe Generale Strauss Turnbull states that Pilkington, the glass manufacturer, has changed dramatically over the past year, and the shares are undervalued. A sleeping giant, it says, is finally awakening.

One of the significant changes it highlights is Pilkington's move into developing markets. It is constructing or acquiring plants in Brazil, Argentina, Chile, Poland and China, which will leave it with over a quarter of its production coming from emerging markets.

Analyst Howard Proctor also highlights the retirement of chairman Sir Anthony Pilkington, bringing to an end five generations of family involvement. His replacement, Nigel Rudd, will bring a further dynamism to play. The shares, at 193p, are attractive for long-term investors, while there is scope for continuing dividend growth.

INVESTORS lucky enough to buy into Zotefoams when it floated at 145p in March have had an extraordinary ride. The former BP subsidiary, bought out from its parent three years ago, now stands at 263p.

With that sort of gain, the results announced by the company last week are probably not enough to ensure continuing institutional support. The foam-maker made pre-tax profits of pounds 3.5m, up from pounds 2.39m. Despite this healthy growth, a current price/earnings ratio of 26 suggests the shares are ripe for profit-taking. Sell now, while good profits are still to be had.

RESULTS from Royal Insurance (348p) shone in comparison with mixed figures from its peers, after it announced record interim profits - pre-tax up 26 per cent to pounds 241m - suggesting every chance of a swollen final dividend. According to calculations by broker BZW, a projected net asset value of 388p by the year-end means the shares are still cheap on this basis alone. On a strong US earnings bounce, it says, they look even cheaper. Buy.

BESPAK, a maker of medical devices such as drug inhalers and tools for keyhole surgery, has attracted positive notices for its new dry-powder inhaler, developed especially for Glaxo. The gizmo allows a more accurate dosage of particular drugs to be delivered to the patient, in a less wasteful fashion than with previous inhalers.

While the company has been busy gearing up on this product, it should also be helped by an improvement in the US healthcare market, as it comes to terms with President Clinton's reforms, and stocks are wound down.

Disappointing results from the US business should be behind management by now, and the shares, at 333p, have good recovery potential. Buy.

NEXT WEEK it is the turn of the ageing lion Hanson to report its third- quarter figures. They will give the markets important clues as to whether the company is back on song, or if it remains less than the sum of its parts. The remedy for companies like this in the old days was to bid for them and break them up, selling off overvalued assets, and keeping those with strong cashflows.

NatWest Securities forecasts pre-tax profits of pounds 325m for the third quarter, against pounds 282m last year. The market expects little to change the shares' underperformance over the past year or so, however. The bid for Eastern makes sound financial sense, especially for the tax breaks, but is otherwise only more of the same: safe earnings, with some potential of reasonable growth. There is little resemblance to the classic Hanson break-up play of old. Buy for the safe income.

PROFITS warnings are nearly always gruesome affairs, for shareholders and management. Rexam's announcement last week that it was suffering from customer destocking was no exception. Management credibility took a further knock, and although Rexam has issued unduly pessimistic forecasts in the past, this is no consolation for investors, who saw the value of their holdings plummet by almost 20 per cent.

The company meanwhile is taking some long-overdue action to improve customer liaison, and will have to run down its own stocks in turn. The question is, do the shares have scope for some recovery, or do they remain a sell? There will almost certainly be a speculative bounce in the next few weeks, but there is little to suggest the risks have been fully accounted for at 425p. Avoid.

Start your day with The Independent, sign up for daily news emails
News
ebooksAn unforgettable anthology of contemporary reportage
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Recruitment Genius: Digital Optimisation Executive - Marketing

£30000 - £35000 per annum: Recruitment Genius: The UK's fastest growing, multi...

Recruitment Genius: Financial Reporting Manager

£70000 - £90000 per annum: Recruitment Genius: A Financial Reporting Manager i...

Recruitment Genius: Payments Operations Assistant

£23000 - £25000 per annum: Recruitment Genius: They win lots of awards for the...

Recruitment Genius: Telephone Debt Negotiator

£13500 - £20000 per annum: Recruitment Genius: This nationwide enforcement com...

Day In a Page

Sepp Blatter resignation: The beginning of Fifa's long road to reform?

Does Blatter's departure mean Fifa will automatically clean up its act?

Don't bet on it, says Tom Peck
Charles Kennedy: The baby of the House who grew into a Lib Dem giant

The baby of the House who grew into a Lib Dem giant

Charles Kennedy was consistently a man of the centre-left, dedicated to social justice, but was also a champion of liberty and an opponent of the nanny-state, says Baroness Williams
Syria civil war: The harrowing testament of a five-year-old victim of this endless conflict

The harrowing testament of a five-year-old victim of Syria's endless civil war

Sahar Qanbar lost her mother and brother as civilians and government soldiers fought side by side after being surrounded by brutal Islamist fighters. Robert Fisk visited her
The future of songwriting: How streaming is changing everything we know about making music

The future of songwriting

How streaming is changing everything we know about making music
William Shemin and Henry Johnson: Jewish and black soldiers receive World War I Medal of Honor amid claims of discrimination

Recognition at long last

Jewish and black soldiers who fought in WWI finally receive medals after claims of discrimination
Beating obesity: The new pacemaker which helps over-eaters

Beating obesity

The new pacemaker which helps over-eaters
9 best women's festival waterproofs

Ready for rain: 9 best women's festival waterproofs

These are the macs to keep your denim dry and your hair frizz-free(ish)
Cycling World Hour Record: Nervous Sir Bradley Wiggins ready for pain as he prepares to go distance

Wiggins worried

Nervous Sir Bradley ready for pain as he prepares to attempt cycling's World Hour Record
Liverpool close in on Milner signing

Liverpool close in on Milner signing

Reds baulk at Christian Benteke £32.5m release clause
On your feet! Spending at least two hours a day standing reduces the risk of heart attacks, cancer and diabetes, according to new research

On your feet!

Spending half the day standing 'reduces risk of heart attacks and cancer'
With scores of surgeries closing, what hope is there for the David Cameron's promise of 5,000 more GPs and a 24/7 NHS?

The big NHS question

Why are there so few new GPs when so many want to study medicine?
Big knickers are back: Thongs ain't what they used to be

Thongs ain't what they used to be

Big knickers are back
Thurston Moore interview

Thurston Moore interview

On living in London, Sonic Youth and musical memoirs
In full bloom

In full bloom

Floral print womenswear
From leading man to Elephant Man, Bradley Cooper is terrific

From leading man to Elephant Man

Bradley Cooper is terrific